HIPK2: A Protein with Potential as A Drug Target (G28996)

Target Name: HIPK2

NCBI ID: G28996

HIPK2

HIPK2: A Protein with Potential as A Drug Target

HIPK2 (PRO0593) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the hydrogen homeostasis, which is the ability of cells to maintain a stable level of hydrogen in their environment. Mutations in the HIPK2 gene have been linked to various diseases, including diabetes, heart disease, and kidney failure.

One of the unique features of HIPK2 is its role in maintaining the stability of the cell's pH, or acid-base balance. HIPK2 helps to regulate the levels of hydrogen ions in the cell, which are responsible for maintaining a pH of 7.0. This is important for the proper functioning of many cellular processes, including muscle contractions, nerve impulses, and the regulation of blood pressure.

HIPK2 is also involved in the regulation of inflammation and cellular signaling. It has been shown to play a role in the regulation of pain sensitivity, and has been linked to the development of certain types of cancer.

In addition to its role in cell signaling and pH regulation, HIPK2 is also thought to be a potential drug target. Its role in maintaining the stability of the cell's pH has led to the development of new treatments for certain types of cancer, such as those that cause acid-base imbalances. Additionally, HIPK2 has been shown to be involved in the regulation of inflammation, which is a major risk factor for a wide range of diseases, including heart disease and diabetes.

The HIPK2 gene has been the focus of much research in recent years, and several studies have identified potential drug targets based on its unique role in cell signaling and pH regulation. One of the most promising areas of research is the use of small molecules to modulate the activity of HIPK2.

One approach to targeting HIPK2 is to use small molecules that can modulate its activity. This is an attractive approach, as it allows for the development of compounds that can be used to treat a wide range of diseases, without the need for specific genetic modifiers.

One of the most promising small molecules that has been shown to modulate the activity of HIPK2 is called N-acyl-伪-ketoglutarate (NAG). NAG is a compound that has been shown to inhibit the activity of HIPK2, which suggests that it may be a useful drug target.

NAG works by inhibiting the activity of the protein kinase kinase (PKG), which is a key regulator of HIPK2's activity. This inhibition allows the levels of NAG to accumulate in the cell, which can lead to the inhibition of HIPK2's activity.

NAG has been shown to be effective in treating a wide range of diseases, including cancer, heart disease, and diabetes. In addition to its potential use as a drug, NAG is also being studied as a potential biomarker for certain types of cancer.

Another small molecule that has been shown to modulate the activity of HIPK2 is called 尾-hydroxy-尾-methylbutyrate (尾-HMB). 尾-HMB is a compound that has been shown to inhibit the activity of HIPK2, which suggests that it may be a useful drug target.

尾-HMB works by inhibiting the activity of the protein kinase kinase (PKG), which is a key regulator of HIPK2's activity. This inhibition allows the levels of 尾-HMB to accumulate in the cell, which can lead to the inhibition of HIPK2's activity..

尾-HMB has also been shown to be effective in treating a wide range of diseases, including cancer, heart disease, and diabetes. In addition to its potential use as a drug, 尾-HMB is also being studied as a potential biomarker for certain types of cancer.

Overall, HIPK2 is a protein that plays a critical role in the regulation of cell signaling and pH balance. Its role in maintaining the stability of the cell's pH has led to the development of new treatments for certain types of cancer. Additionally, HIPK2 is also thought to be a potential drug target, and several small molecules have been shown to modulate its activity. Further research is needed to fully understand the role of HIPK2 in

Protein Name: Homeodomain Interacting Protein Kinase 2

Functions: Serine/threonine-protein kinase involved in transcription regulation, p53/TP53-mediated cellular apoptosis and regulation of the cell cycle. Acts as a corepressor of several transcription factors, including SMAD1 and POU4F1/Brn3a and probably NK homeodomain transcription factors. Phosphorylates PDX1, ATF1, PML, p53/TP53, CREB1, CTBP1, CBX4, RUNX1, EP300, CTNNB1, HMGA1, ZBTB4 and DAZAP2. Inhibits cell growth and promotes apoptosis through the activation of p53/TP53 both at the transcription level and at the protein level (by phosphorylation and indirect acetylation). The phosphorylation of p53/TP53 may be mediated by a p53/TP53-HIPK2-AXIN1 complex. Involved in the response to hypoxia by acting as a transcriptional co-suppressor of HIF1A. Mediates transcriptional activation of TP73. In response to TGFB, cooperates with DAXX to activate JNK. Negative regulator through phosphorylation and subsequent proteasomal degradation of CTNNB1 and the antiapoptotic factor CTBP1. In the Wnt/beta-catenin signaling pathway acts as an intermediate kinase between MAP3K7/TAK1 and NLK to promote the proteasomal degradation of MYB. Phosphorylates CBX4 upon DNA damage and promotes its E3 SUMO-protein ligase activity. Activates CREB1 and ATF1 transcription factors by phosphorylation in response to genotoxic stress. In response to DNA damage, stabilizes PML by phosphorylation. PML, HIPK2 and FBXO3 may act synergically to activate p53/TP53-dependent transactivation. Promotes angiogenesis, and is involved in erythroid differentiation, especially during fetal liver erythropoiesis. Phosphorylation of RUNX1 and EP300 stimulates EP300 transcription regulation activity. Triggers ZBTB4 protein degradation in response to DNA damage. In response to DNA damage, phosphorylates DAZAP2 which localizes DAZAP2 to the nucleus, reduces interaction of DAZAP2 with HIPK2 and prevents DAZAP2-dependent ubiquitination of HIPK2 by E3 ubiquitin-protein ligase SIAH1 and subsequent proteasomal degradation (PubMed:33591310). Modulates HMGA1 DNA-binding affinity. In response to high glucose, triggers phosphorylation-mediated subnuclear localization shifting of PDX1. Involved in the regulation of eye size, lens formation and retinal lamination during late embryogenesis

The "HIPK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIPK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets